benmelstobart + paclitaxel + carboplatin

This is a combination regimen consisting of benmelstobart, paclitaxel, and carboplatin. Paclitaxel is a microtubule-stabilizing agent that inhibits cell division by promoting the assembly of microtubules and preventing their depolymerization, leading to apoptosis in rapidly dividing cancer cells. Carboplatin is a platinum-based chemotherapeutic that forms DNA crosslinks, inhibiting DNA synthesis and function, resulting in cell death. Benmelstobart appears to be an investigational or less widely documented agent; based on naming conventions it may be a monoclonal antibody or immunotherapy (though no direct data was found in the provided sources). The combination of paclitaxel and carboplatin is well-established for treating various cancers including ovarian, lung, endometrial, cervical cancer, and others[1][2][3][5]. The addition of benmelstobart would likely aim to enhance antitumor efficacy through an additional mechanism such as immune modulation.